 |
 |
 |
 |
 |
 |
 |
|
 |
 |
Press ReleasesGenstruct Announces Expansion of Relationship with PfizerCambridge, Mass. — November 8, 2004 — Genstruct Inc., a knowledge-driven discovery company, announced today that it has signed an agreement with Pfizer to collaborate on a variety of research projects to help better understand complex diseases. This deal is part of a continuing, multi-year relationship Genstruct has developed with Pfizer. Terms of the partnership are not being disclosed. This new arrangement will include research projects with several Pfizer units, including Worldwide Safety Sciences, the Proteomics Global Center of Excellence, and Clinical Sciences. Genstruct will use its Molecular EpistemicsTM Platform to generate hypotheses to reveal underlying mechanisms of action and toxicity to help Pfizer prioritize and develop new medicines for treating complex diseases. "We are pleased to be growing our relationship with Pfizer," said Keith O. Elliston, Ph.D., president and CEO of Genstruct. "We have developed a novel approach to mechanism discovery and this agreement with the world's premier pharmaceutical research and development organization should provide additional validation of our Molecular EpistemicsTM Platform. Through this relationship, we will work with Pfizer scientists to identify mechanisms and biomarkers to improve leads and optimize clinical trial design and execution." About Genstruct Founded in 2002, Genstruct is a knowledge-driven discovery company focused on pioneering new approaches to the understanding and treatment of complex diseases in the areas of oncology, metabolic disorders and inflammation. Genstruct has developed the Molecular EpistemicsTM Platform for the discovery of biomarkers, disease pathways and compound mechanisms of action (MOA). This platform is comprised of a suite of patent-pending technologies that includes the Knowledge AssemblyTM process, which enables continuous and rapid construction of addressable biological models, as well as the Epistemics EngineTM System for mining and refining the models for mechanism discovery and validation. Genstruct engages in internal discovery and external development partnerships that apply the Molecular Epistemics Platform to accelerate and increase the output of drug discovery and development programs. The privately held company is based in Cambridge, Mass., and its investors include Flagship Ventures and A. M. Pappas & Associates. For more information, please visit www.genstruct.com. Contact: Karen Higgins A & E Communications for Genstruct (610) 831-5723 khiggins@aandecomm.com Return to Press Releases |
 |
|
 |
| One Alewife Center | Cambridge, MA 02140 | (617) 547-5421 | sitemap |